Dr Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and oesophageal program. His clinical and translational research is centred on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, the NCI esophagogastric task force, and the NCCN guideline committees for gastric and oesophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, and he currently serves as the AGA Research Foundation’s Gastric Cancer Foundation Ben Feinstein Memorial Research Scholar Award in Gastric Cancer. As a member of the gastrointestinal cancer group at MGH Dr Klempner conducts clinical trials and translational research with new targeted agents and immune therapies and is active in gastroesophageal cancer advocacy and education.
Last update: March 2022